Phio Pharmaceuticals Reports Positive Trial Results Amid Stock Volatility
Phio Pharmaceuticals Corp's stock fell 21.09% after crossing below its 5-day SMA, reflecting significant volatility in the market.
The decline comes despite positive news regarding the company's PH-762, which achieved an 85% pathological response rate in its Phase 1b clinical trial for skin cancers. Additionally, the company plans to submit for FDA guidance on clinical study design for PH-762 in Q2 2026, indicating a strong commitment to the drug's development. However, the stock's recent performance suggests profit-taking and market caution, as it approaches its 52-week lows.
This volatility highlights the challenges Phio Pharmaceuticals faces in maintaining investor confidence, even with promising clinical results and future FDA plans.
Trade with 70% Backtested Accuracy
Analyst Views on PHIO
About PHIO
About the author
Phio Pharmaceuticals Stock Volatility Without Clear Justification
- Positive Clinical Trial Results: Phio Pharmaceuticals' PH-762 demonstrated an 85% pathological response rate in its Phase 1b clinical trial involving 22 patients with skin cancers, with no serious adverse events reported by the Safety Monitoring Committee, indicating a promising outlook for this potential non-surgical treatment.
- FDA Submission Plans: The company is targeting an FDA submission for clinical study design guidance for PH-762 in Q2 2026, with plans to commence cGMP material manufacturing in the second half of 2026, reflecting ongoing commitment and confidence in the drug's development.
- Stock Price Volatility: Despite a nearly 15% increase on Wednesday, the stock fell 4.65% to $1.23 on Thursday, indicating profit-taking behavior and positioning closer to its 52-week lows, which suggests market caution regarding the stock's future performance.
- Mixed Technical Indicators: The stock is currently trading 18.4% above its 20-day simple moving average but 18.3% below its 100-day simple moving average, with a neutral RSI of 66.61 and a bullish MACD above its signal line, indicating mixed momentum in the short to medium term.
Phio Pharmaceuticals Reports Positive Phase 1b Results for PH-762
- Clinical Trial Results: Phio Pharmaceuticals announced positive outcomes from its Phase 1b trial for PH-762, with the Safety Monitoring Committee confirming no serious adverse events across all five dose escalation cohorts, indicating strong safety profiles.
- Tumor Response Rate: The highest dose cohort achieved an 85% pathological response rate, with complete tumor clearance in four out of six responders, highlighting PH-762's potential as a treatment for skin cancers.
- Next Steps: The company plans to submit an FDA application in Q2 2026 for guidance on clinical study design for PH-762, while also aiming to commence cGMP material manufacturing in the second half of 2026 to support future trials.
- Market Performance Analysis: Despite a 51.11% increase to $1.36 on Tuesday, Phio's stock remains below its 20-day and 50-day simple moving averages, reflecting a bearish trend in the short term.
Phio Pharmaceuticals Initiates Toxicology Study for PH-762, Aiming for 2026 Market Launch
- Critical Research Initiation: Phio Pharmaceuticals has commenced a toxicology study for PH-762, a crucial step mandated by the FDA that aims to pave the way for human pivotal trials, thereby accelerating the drug development process and enhancing market competitiveness.
- Clear Commercialization Goals: The company plans to launch a commercially viable product that meets FDA current Good Manufacturing Practices by 2026, a target supported by recent financing, demonstrating Phio's proactive response to market demands.
- Clinical Trial Progress: In the ongoing Phase 1b trial, 6 out of 18 skin cancer patients achieved 100% tumor clearance, indicating PH-762's potential as a non-surgical treatment option for skin cancers, which could significantly impact treatment paradigms.
- Strengthened Strategic Partnerships: Phio has entered into a comprehensive drug substance development services agreement with a U.S. manufacturing company, ensuring that clinical supplies for PH-762 meet cGMP standards, which will enhance production capabilities and expedite the product's market entry.
Three Penny Stocks to Keep an Eye on as of November 4, 2025
Penny Stocks to Watch: Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are highlighted as top penny stocks to monitor on November 4, 2025, based on their high Dollar Volume and market activity.
Generation Essentials Group: This France-based media company saw a Dollar Volume of $308 million and a 123% stock price increase after announcing a share repurchase program and plans to acquire hotels globally.
Phio Pharmaceuticals: The biotech firm experienced a Dollar Volume of $301.44 million despite a 9.3% decline in stock price, following positive trial results for its cancer treatment, which initially surged by nearly 75%.
Caribou Biosciences: With a Dollar Volume of $166.10 million, Caribou's stock reached a 52-week high after positive analyst ratings and promising data on its CRISPR gene-editing therapies for difficult-to-treat cancers.
What’s Driving the Surge in Phio Pharmaceuticals Stock Today?
Phio Pharmaceuticals Update: Shares of Phio Pharmaceuticals Corp. rose significantly after announcing positive results from its ongoing Phase 1b trial for treating cutaneous squamous cell carcinoma (cSCC), with one patient achieving 100% tumor clearance.
Trial Results: Out of 18 patients treated, six showed complete responses, while others demonstrated varying degrees of tumor clearance, and no patients experienced clinical progression of the disease.
Stock Performance: The stock surged over 30% on Monday, trading at $2.73, and is currently above its 50-day and 200-day moving averages, indicating a strong upward trend.
Market Sentiment: The bullish sentiment surrounding Phio Pharmaceuticals may attract further investor interest, although the stock faces potential resistance near its 52-week high of $9.78.
Monday's Major Stock Market Highlights: Morning News Summary!
Market Overview: Traders are encouraged to explore significant stock market stories as the week begins, highlighting key happenings to watch for on Monday.
Source for More Information: Additional top stock market stories can be found at TipRanks, providing further insights for traders.
Phio Pharmaceuticals Stock Volatility Without Clear Justification
- Positive Clinical Trial Results: Phio Pharmaceuticals' PH-762 demonstrated an 85% pathological response rate in its Phase 1b clinical trial involving 22 patients with skin cancers, with no serious adverse events reported by the Safety Monitoring Committee, indicating a promising outlook for this potential non-surgical treatment.
- FDA Submission Plans: The company is targeting an FDA submission for clinical study design guidance for PH-762 in Q2 2026, with plans to commence cGMP material manufacturing in the second half of 2026, reflecting ongoing commitment and confidence in the drug's development.
- Stock Price Volatility: Despite a nearly 15% increase on Wednesday, the stock fell 4.65% to $1.23 on Thursday, indicating profit-taking behavior and positioning closer to its 52-week lows, which suggests market caution regarding the stock's future performance.
- Mixed Technical Indicators: The stock is currently trading 18.4% above its 20-day simple moving average but 18.3% below its 100-day simple moving average, with a neutral RSI of 66.61 and a bullish MACD above its signal line, indicating mixed momentum in the short to medium term.
Phio Pharmaceuticals Reports Positive Phase 1b Results for PH-762
- Clinical Trial Results: Phio Pharmaceuticals announced positive outcomes from its Phase 1b trial for PH-762, with the Safety Monitoring Committee confirming no serious adverse events across all five dose escalation cohorts, indicating strong safety profiles.
- Tumor Response Rate: The highest dose cohort achieved an 85% pathological response rate, with complete tumor clearance in four out of six responders, highlighting PH-762's potential as a treatment for skin cancers.
- Next Steps: The company plans to submit an FDA application in Q2 2026 for guidance on clinical study design for PH-762, while also aiming to commence cGMP material manufacturing in the second half of 2026 to support future trials.
- Market Performance Analysis: Despite a 51.11% increase to $1.36 on Tuesday, Phio's stock remains below its 20-day and 50-day simple moving averages, reflecting a bearish trend in the short term.
Phio Pharmaceuticals Initiates Toxicology Study for PH-762, Aiming for 2026 Market Launch
- Critical Research Initiation: Phio Pharmaceuticals has commenced a toxicology study for PH-762, a crucial step mandated by the FDA that aims to pave the way for human pivotal trials, thereby accelerating the drug development process and enhancing market competitiveness.
- Clear Commercialization Goals: The company plans to launch a commercially viable product that meets FDA current Good Manufacturing Practices by 2026, a target supported by recent financing, demonstrating Phio's proactive response to market demands.
- Clinical Trial Progress: In the ongoing Phase 1b trial, 6 out of 18 skin cancer patients achieved 100% tumor clearance, indicating PH-762's potential as a non-surgical treatment option for skin cancers, which could significantly impact treatment paradigms.
- Strengthened Strategic Partnerships: Phio has entered into a comprehensive drug substance development services agreement with a U.S. manufacturing company, ensuring that clinical supplies for PH-762 meet cGMP standards, which will enhance production capabilities and expedite the product's market entry.
Three Penny Stocks to Keep an Eye on as of November 4, 2025
Penny Stocks to Watch: Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are highlighted as top penny stocks to monitor on November 4, 2025, based on their high Dollar Volume and market activity.
Generation Essentials Group: This France-based media company saw a Dollar Volume of $308 million and a 123% stock price increase after announcing a share repurchase program and plans to acquire hotels globally.
Phio Pharmaceuticals: The biotech firm experienced a Dollar Volume of $301.44 million despite a 9.3% decline in stock price, following positive trial results for its cancer treatment, which initially surged by nearly 75%.
Caribou Biosciences: With a Dollar Volume of $166.10 million, Caribou's stock reached a 52-week high after positive analyst ratings and promising data on its CRISPR gene-editing therapies for difficult-to-treat cancers.
What’s Driving the Surge in Phio Pharmaceuticals Stock Today?
Phio Pharmaceuticals Update: Shares of Phio Pharmaceuticals Corp. rose significantly after announcing positive results from its ongoing Phase 1b trial for treating cutaneous squamous cell carcinoma (cSCC), with one patient achieving 100% tumor clearance.
Trial Results: Out of 18 patients treated, six showed complete responses, while others demonstrated varying degrees of tumor clearance, and no patients experienced clinical progression of the disease.
Stock Performance: The stock surged over 30% on Monday, trading at $2.73, and is currently above its 50-day and 200-day moving averages, indicating a strong upward trend.
Market Sentiment: The bullish sentiment surrounding Phio Pharmaceuticals may attract further investor interest, although the stock faces potential resistance near its 52-week high of $9.78.
Monday's Major Stock Market Highlights: Morning News Summary!
Market Overview: Traders are encouraged to explore significant stock market stories as the week begins, highlighting key happenings to watch for on Monday.
Source for More Information: Additional top stock market stories can be found at TipRanks, providing further insights for traders.
